Diana Ernst, RPh

As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.

The approval was based on data from the phase 3 TOPAZ-1 trial.

Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.

Belzutifan is a potent and selective inhibitor of HIF-2α.

To prove clinical benefit, the FDA requires manufacturers to conduct confirmatory trials, also known as a phase 4 studies.

Fully vaccinated individuals can visit with other fully vaccinated people, or unvaccinated people from a single household who are at low risk for severe COVID-19 disease, indoors without wearing masks or physical distancing.

Lorbrena is a third generation ALK tyrosine kinase inhibitor.

Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.

Oblato plans to evaluate OKN-007 for diffuse intrinsic pontine glioma in a phase 1/2 trial this year.

The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.